Our Strategy. Widening participation in Higher Education continues to be a key strategic aim for the University of Portsmouth, as highlighted through our University Strategy 2015-2020; which states our commitment to “raising expectations and creating ladders of opportunity for people in our region to take part in higher education”. Our Education Strategy to 2020 places a strong focus on student retention and employment and highlights our vision to enhance educational aspirations and create high-quality, relevant, lifelong education opportunities through working in partnership, including with schools, colleges, employers and alumni. Our strategic ambitions against this principle are as follows: We will make a positive, clear and significant contribution to encouraging, extending, and sustaining the engagement of learners, and to inspiring and enabling their access to and success in higher education; We will continue and extend our commitment to a partnership approach to outreach activities and our role in raising educational aspirations in our region; We will develop, promote and deliver a broader and more flexible range of routes for entry to the University, both for individuals and via strategic partnerships with educational institutions and employers, regionally, nationally and internationally; We will develop a variety of flexible learning programmes in partnership with employers and, where appropriate, professional and statutory bodies, as a means to both grow and diversify our student community; We will develop and deliver an enhanced offer of continuous and flexible professional development courses, including named awards through credit accumulation. Current initiatives that will contribute to widening participation include the planned appointment of an Associate Pro Vice-Chancellor for Education Partnerships who will focus on establishing feeder routes from local schools and colleges in to the University; and new provision including apprenticeships, more flexible programmes that suit the needs of mature students and other changes to our range of programmes to broaden their appeal.
Our Strategy. Our focus is to develop and commercialize novel, non-opioid, and non-addictive therapies to address, safely and effectively, the significant unmet medical need of chronic pain or treat conditions that cause pain. The principal elements of our strategy to achieve this mission are the following: ● License, acquire, develop, and create novel, non-opioid and non-addictive therapies by leveraging our understanding of pain biology to address the large and growing problem of pain. While innovation in medical sciences has led to exciting new treatment options in many disease areas, pain has seen limited innovation in recent years. We have a deep understanding of the pathophysiology of pain and diseases that cause pain. We intend to leverage this understanding to bring innovation in the pain treatment paradigm through targeted acquisitions of companies or assets in development. Our advisors and doctors have years of collective experience in leadership positions at institutions and substantial scientific experience and understand the complexity of designing and executing clinical trials for and developing therapies. ● Advance the development of JAN101, designed for the treatment of patients with PAD and pain associated with the disease. There are limited therapeutic options available for patients with PAD and we believe that JAN101 has the potential to transform the standard of care to a twice-a-day pill to improve moderate-to-severe PAD substantially. ● Leverage clinical activity of JAN101 possibly to expand into new indications. The Company is in discussion with multiple researchers about expanding JAN101’s use into other indications. JanOne will provide the researchers previously manufactured clinical supplies of JAN101 for use in their clinical trials. ● Advance JAN101 through clinical development and pursue development of additional product candidates through acquisitions. Our objective is to build a well-balanced, multi-asset portfolio targeting the large population of patients with chronic and acute pain. To achieve this, in addition to JAN101, we intend to pursue partnerships, licensing agreements, and potential acquisitions of other pharma companies. We continue our search for assets with indications where we believe they could have meaningful impact and address the large unmet medical need. In addition, we may choose to selectively in-license or acquire complementary product candidates by leveraging the insights, network, and experience of our team. ● Maxi...
